Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Takeda
Takeda
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Takeda's NDA for metastatic colorectal cancer treatment
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance
Takeda Pharmaceutical to acquire GammaDelta Therapeutics
Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance
Takeda to evaluate Aptamer Group reagents for drug development
Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance
Adaptate Biotherapeutics raises $18 m in Series A2 funding
The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance
Novadiscovery enters clinical simulation collaboration with Takeda
This agreement builds on an existing relationship between the companies that began in 2017
Manufacturing
Future thoughts about pharmaceutical manufacturing
COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Manufacturing
Takeda opens cell therapy manufacturing facility in Boston
The next-generation cell therapies will initially focuse on oncology with potential to expand into other therapeutic areas
Subscribe now